학술논문

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigatorʼs choice in relapsed or refractory mantle cell lymphoma
Document Type
Academic Journal
Source
British Journal of Haematology. Jan 01, 2018 180(2):224-235
Subject
Language
English
ISSN
0007-1048